Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting
Go back to Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting| CELLDEX THERAPEUTICS, Inc. (NASDAQ: CLDX) | Delayed: 33.41 +0.98 (3.02%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $32.43 | 52 Week High | $18.62 | |||
| Open | $32.90 | 52 Week Low | $2.85 | |||
| Day High | $33.46 | P/E | N/A | |||
| Day Low | $32.26 | EPS | $-1.02 | |||
| Volume | 1,957,841 | |||||
